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Abstract
Background: Borderline Personality Disorder (BPD) is a common mental disorder associated with raised mortality,
morbidity and substantial economic costs. Although complex psychological interventions have been shown to be
useful in the treatment of BPD, such treatments are expensive to deliver and therefore have limited availability and
questionable cost-effectiveness. Less complex interventions are required for the management of BPD. A Joint Crisis
Plan (JCP) is a record containing a service user’s treatment preferences for the management of future crises and is
created by the service user with the help of their treating mental health team. These plans have been shown to to
be an effective way of reducing compulsory treatment in people with psychosis. However, to date they have not
been used with individuals with BPD. This exploratory trial will examine whether use of a JCP is an effective and
cost-effective intervention for people with BPD for reducing self-harm.
Methods/Design: In this single blind exploratory randomized controlled trial, a total of 120 participants (age >18
years with a primary diagnosis of DSM-IV borderline personality disorder) will be recruited from community mental
health teams and, after completing a baseline assessment, will be assigned to one of two conditions: (1) a Joint
Crisis Plan, or (2) treatment as usual. Those allocated to the JCP condition will take part in a facilitated meeting, the
purpose of which will be to agree the contents of the plan. Following the meeting, a typed version of the JCP will
be sent to the patient and to any other individuals specified by the participant. All participants will be followed-up
at 6 months. The primary outcome measures are: any self-harm event, time to first episode of self-harm and
number of self-harm events over the follow-up period. Secondary outcome measures are length of time from
contemplation to act of self-harm, help-seeking behaviour after self-harm, cost, working alliance, engagement with
services and perceived coercion. Other outcome variables are quality of life, social impairment and satisfaction with
treatment.
Discussion: Results of this trial will help to clarify the potential beneficial effects of JCPs for people with BPD and
provide information to design a definitive trial.
Trial Registration: Current Controlled Trials ISRCTN12440268
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Borderline personality disorder (BPD) is characterised by
a pervasive pattern of instability in emotional regulation,
impulse control, interpersonal relationships, and self-
image [1]. The condition occurs globally with a commu-
nity prevalence of 0.7%, although the prevalence is far
higher in clinical populations where it affects up to 20%
of psychiatric outpatients [2] and is associated with high
rates of co-morbidity and significantly increased health
service costs [3,4]. People with BPD are more likely to
experience adverse life events and their ability to cope
with such events is impaired by poor problem-solving
skills [5]. Self-harm is often employed by people with
BPD as a way of regulating their level of arousal at
times of crises, however, such behaviour puts them at
increased risk of suicide [6].
A Joint Crisis Plan (JCP) is a record containing a ser-
vice user’s treatment preferences for the management of
future crises. It is developed by a mental health service
user in collaboration with staff and aims to increase the
service user’s level of involvement in their own treatment
[7]. Held by the service user, it contains his or her treat-
ment preferences for any future psychiatric crisis, when
he or she may be less able to express clear views. The
JCP is created at a meeting between the service user,
those involved in his or her care, and an independent
facilitator not involved in the service user’s care. The ser-
vice user is provided with a template (a list of subhead-
ings the service user may or may not wish to include in
the plan) and the team then openly discusses with the
service user the advantages and disadvantages of the var-
ious subheadings included. The JCP is therefore pro-
duced collaboratively between the service user and his or
her treating team with the aim of the plan being con-
sulted and followed during a future crisis. JCPs improve
the information available to clinical staff about the man-
agement of a crisis and empower service users by ensur-
ing that they are actively involved in the generation of
their own crisis plan. JCPs have been shown to be an
effective way of reducing compulsory treatment in people
with psychosis [8], help service users feel more in control
of their mental health problems [9] and may also reduce
admission rates to hospital [10].
The treatment of people with BPD is frequently char-
acterized by conflicts with health professionals and such
conflicts are particularly likely to arise in the manage-
ment of self-harming behaviour [11]. Moreover, the ces-
sation of self-harming behavious is often associated with
an individual’s ability to assert greater control over their
life [12]. Given that the JCP is designed to facilitate a
more collaborative relationship with staff, we hypothe-
sise that JCPs may be an effective way of managing self-
harm in people with BPD. In this article, we describe
the proposed methods of an exploratory randomized
controlled trial (RCT) that is designed to estimate the
effectiveness and cost-effectiveness of JCPs on self-
harming behaviour in people with BPD and to deter-
mine the most effective methods of data collection to
inform future studies.
Methods/Design
Overview
The “Joint crisis plans for people who Self-Harm”
(JOSHUA) study is a single centre exploratory rando-
mized controlled trial of JCPs compared with a treat-
ment as usual control condition for people with BPD
and a history of self-harming behaviour. The total dura-
tion of the study will be two years, to allow for the
recruitment to target numbers of participants, provision
of the intervention, follow-up assessments, and data
analysis, using intention-to-treat methods.
Aims
The JOSHUA study has the following aims:
1. To determine whether JCPs for people with BPD
have a beneficial effect on self-harming behaviour,
and to estimate the likely range of effects consistent
with the use of JCPs.
2. To determine the cost-effectiveness of JCPs for
people with BPD.
Eligibility criteria
Inclusion criteria
i) Age greater than or equal to 18 years
ii) Current contact with a Community Mental
Health Team (CMHT)
iii) A primary diagnosis of DSM-IV Borderline Per-
sonality Disorder
iv) An episode of self-harm in the previous year
Exclusion criteria
(i) Age less than 18 years
(ii) Unable to give informed consent.
(iii) Unable to speak English. Fluency in English is
necessary to complete the assessment instruments
(many of which have not been validated in non-English
languages) and to fully participate in the development of
the Joint Crisis Plans.
(iv) Primary diagnosis of psychosis
(v) Current in-patients will not be recruited to avoid
any perceived potential coercion to participate, nor any
patient subject to a compulsory community treatment
order.
No other exclusions will be made, to maximise the
external validity of the trial.
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The research team will approach local Community
Mental Health Teams (CMHTs) and present the study
to staff, allowing them to ask questions and become
familiar with the study. Team managers will then be
asked to identify all potentially eligible participants
under the care of their team. Research workers will then
approach potential participants through their care coor-
dinator and invite them to a meeting in order to discuss
the study in detail. At this meeting they will be given a
full description of the study and provided with a written
information sheet. If willing to participate, they will be
invited to sign the consent form. A baseline interview
will then be conducted by the research worker, either at
this point or at a subsequent meeting depending on the
wishes of the participant. In a pilot study of 13 partici-
pants (described further below) in which feasibility of
administering the intervention and collecting data were
examined, the average duration of the baseline interview
was 45 minutes, with no drop-outs. Once the baseline
interview has been conducted, the participant will be
randomised independently, to either the intervention or
control group. Figure 1 displays the flow of participants
through the trial.
Randomisation procedure and methods to minimise bias
Participants will be randomised using the method of
minimisation with a random component stratified by
alcohol misuse [as measured by the Alcohol Use Disor-
ders Identification Test (AUDIT) [13]] and depression
[as measured by the Hospital Anxiety and Depression
Scale (HADS) [14]]. The randomisation will be managed
by the Clinical Trials Unit (CTU) at the Institute of Psy-
chiatry. Confirmation of eligibility, consent, and baseline
data will be obtained prior to randomisation. Bias in the
recruitment and randomisation process will be avoided
by having randomisation done centrally by the CTU,
and hence concealment maintained from the investiga-
tors, and by keeping a log of all service users rando-
mised and including them all in the analysis. The
research worker collecting outcome data will be blinded
to the allocation. Some outcome data will be obtained
from electronic patient records, even for participants
lost to follow-up interview. This will include any epi-
sodes of self harm, hospital admissions and service use
recorded in the electronic records. Bias in the collection
of outcome data will also be minimised by the use of
standardised objective assessments and by blinding the
researchers as far as possible to service user allocation.
There will be specific instructions to participants and
clinical teams not to disclose the treatment details of
any study participant. Every effort will be made to maxi-
mise the single blindness of research workers, whose
‘best guesses’ of treatment arm status will be assessed
after the final assessment in order to test whether their
blindness was successfully maintained.
Intervention
Development of the experimental intervention
The JCP was originally developed for patients with psy-
chotic illnesses. For the purposes of this study, the JCP
template and procedure needed to be altered in order to
make it relevant to people with BPD. For example, the
original JCP template used constructs such as “relapse”
which are less applicable to people with BPD. Adapta-
tion of the JCP was informed by three distinct phases.
Firstly, a series of focus groups was convened with men-
tal health professionals and service users during which
necessary adaptations were discussed. After the JCP
template was amended on the basis of the feedback
from the focus groups, the amended version was
emailed out to members of the focus groups for further
refining. Secondly, an email consultation exercise was
conducted with leading UK clinical academics (n = 16)
to assess the relevance of each item in the JCP menu.
The final JCP template contained information for the
service user, information for health professionals and
details of practical help which the service user might
require when in a future crisis. The procedure for devel-
oping a JCP for patients with a psychotic illness involved
a joint planning meeting with the clinical team, includ-
ing a doctor, because of the likelihood of treatment pre-
ferences or refusals involving medication. However, this
was considered to be less relevant to patients with BPD,
so the planning meeting would take place with the care
coordinator, but a doctor would be consulted if
required. Finally, we examined the feasibility of conduct-
ing JCP planning meetings and data collection methods
with a small convenience sample of BPD service users
(n = 13). Results from this case series indicated that not
o n l yw a st h ep r o c e s so fd e v e l o p i n gJ C P sf e a s i b l e ,b u t
also that the JCPs were potentially useful - participants
in the case series reported using the JCPs when experi-
encing crises, with some stating that they had reduced
their self-harming behaviour since creating their JCP.
Administration of the experimental intervention
In the trial, a clinically experienced research worker will
organise a meeting with each participant randomised to
receive a JCP. The research worker will introduce a list
of topics to be considered for inclusion in the JCP and
will then organise a meeting between the participant
and their care coordinator, when the JCP contents will
be finalised. The research worker will then produce a
typed version of the JCP and copies will be sent to all
those whom the participant specifies. A copy of the JCP
will also be attached to each participant’s electronic psy-
chiatric case record in order to maximise dissemination
of the plan.
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The participants in the control condition will receive
treatment as usual (TAU), as this provides a fair compari-
son with routine clinical practice and will answer the
question of whether JCP use is superior to current stan-
dard care. TAU includes, as a part of the Care Pro-
gramme Approach (CPA), the need for service users to
receive written copies of their care plan, including a pre-
scriptive ‘crisis contingency plan’, in addition to regular
contact with a care coordinator or allocated member of
the clinical team. We anticipate that the CPA arrange-
ments will be applied equally by routine services to inter-
vention and control groups. Those participants allocated
to receive a JCP will also continue to receive usual treat-
ment from their CMHT in addition to creating a JCP.
We do not anticipate that TAU will change during the
course of the trial and will be documenting what TAU
consists of through our collection of service use data.
Randomised 
(N= 120) 
Baseline assessment 
Allocated to JCP 
(N = ) 
Allocated to treatment as usual 
(N = ) 
Screened for eligibility  
(N= ) 
Excluded 
Not meeting inclusion criteria (N= ) 
Refused to participate (N= )
Lost to follow-up 
(N = ) 
Analysed  
(N = ) 
Lost to follow-up 
(N = ) 
Analysed  
(N = ) 
Excluded 
Not meeting inclusion criteria 
(N= )
Figure 1 CONSORT flow chart of JOSHUA trail design.
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Baseline assessments
(i) Socio-demographic details - age, sex, ethnicity,
employment, educational, marital status
(ii) Details of self-harming behaviour over the preced-
ing 6 months - measured using questions from Hawton
et al [15]
(iii) Personality disorder status - Structured Clinical
Interview for DSM-IV personality disorders (SCID-II)
[16] - BPD subsection
(iv) Functional impairment - Work & Social Adjust-
ment Schedule (WSAS) [17]
(v) Engagement with services - Service Engagement
Scale [18]
(vi) Working Alliance - Working Alliance Inventory-
Short Form (client version) (WAI-S) [19]
(vii) WAI-S (therapist version)
(viii) Health-related quality of life - Euroquol (EQ-5D)
[20]
(ix) Satisfaction with care - Client Satisfaction Ques-
tionnaire (CSQ) [21]
(x) Perceived coercion - Treatment Experience Scale
[22]
(xi) Service use - Adult Service Use Schedule (ADSUS)
[23]
(xii) Alcohol use - Alcohol Use Disorders Identifica-
tion Test (AUDIT) [13]
(xiii) Illicit substance use - Questionnaire on use of
illicit substances taken over last year
(xiv) Emotional symptoms - Hospital Anxiety and
Depression Scale (HADS) [14]
Additionally, socio-demographic data and length of
practice data will be collected for care coordinators,
using a proforma developed during the previous pilot
work.
Follow-up assessments
Six months after randomisation, all participants will be
followed-up. A research worker, blinded to treatment
allocation, will arrange a convenient time to meet with
the participant in order to complete the following
measures:
i) Time to first act of self-harm (if any)
ii) Number of self-harm episodes over the preceding
6-month period
iii) Regarding the most recent act of self-harm - length
of time from contemplation of self-harm to self-harm
act
iv) Regarding the most recent act of self-harm - help-
seeking behaviour prior to event (see 10.3)
v) WAI-S (client + therapist)
vi) WSAS
vii) Service Engagement Scale
viii) Treatment Experience Scale
ix) EQ-5D
x) CSQ
xi) ADSUS
Self-harm follow-up data
Variables (i) and (ii) will be gathered from the following
sources:
1. The follow-up interviews with participants at
6-months - participants will be asked to recall the
approximate number of self-harm events occurring over
the preceding six months. Variables (iii) and (iv) will be
gathered using questions derived from Hawton et al
[15].
2. Diaries: all participants will be supplied with a sim-
ple diary/calendar and will be asked to record all self-
harm events on this (by simply circling the days of the
month on which self-harm events occurred).
3. Electronic psychiatric case records.
Sample size
Assumptions
For the purposes of the power calculation, the propor-
tion of participants self-harming within the two groups
has been chosen as the primary outcome, as this is likely
to be the most consistent across the data collection
methods, the most complete, and is more amenable to
cost-effectiveness analysis. In a previous large RCT (the
POPMACT trial) of cognitive therapy versus TAU for
people who self-harmed, 36% of patients in the TAU
group had a self-harm episode over the first 6 months
of the trial [24]. We envisage that the incidence of self-
harm in our TAU will be similar to the POPMACT
trial. In an RCT of ‘green cards’ versus TAU for first
presentation self-harm, the risk of self-harm after rando-
misation in the green card group was 37% (95%CI 14%
to 97%) of the risk in the TAU group [25]. Given that
the green card is not individualised whereas JCPs will
b e ,i tw i l lb ea s s u m e dt h a tt h eJ C Pi n t e r v e n t i o nw o u l d
result in a larger effect, with a lower proportion (one
third) of individuals at risk of self-harm since randomi-
sation (33%).
Power calculation
Participants will be followed up for a minimum of six
months with a predicted 36% and 12% of participants
repeating self harm (including serious threats) in the
TAU group and JCP intervention group respectively. On
the basis of these predictions, an overall sample of 114
(randomised 1:1 to TAU: JCPs) would provide 80%
power to detect an observed difference between TAU
and JCPs based on a 2-sided test at the 5% significance
level. This will be increased to 120 to allow a small loss
i nt h ea d m i n i s t r a t i v ed a t ao ns e l f - h a r m .T h i ss a m p l ei s
also large enough to provide 80% power to detect a con-
stant hazard ratio between the groups of 0.29 with pro-
portions of events in the two groups as stated above,
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a fixed time of follow-up and an estimated 10% dropout.
Statistical analysis plan
An intention-to-treat analysis will be applied in the first
instance (i.e. analysing all available data from rando-
mised participants). The three data collection methods
for the outcome of self-harm (i.e., participant interviews,
diaries and electronic case records) are likely to differ
on the amount of missing data. We will compare pro-
portions of missing data using chi-square tests and
agreement between data collection methods using Lin’s
Concordance Correlation Coefficient. Preliminary effec-
tiveness estimates: Logistic regression will be used to
compare proportions of patients that have self-harmed
during the follow-up period in the two groups. Analysis
of ‘time to first self harm’ outcome will also be con-
ducted using survival analysis methods; log-rank test for
bivariate comparisons and cox’s proportional hazards to
adjust for gender, stratification variables and time spent
on treatment prior to randomisation. Other outcome
assessments (continuous and binary) will be compared
between the treatment groups at 6-month follow-up
using t-tests, chi-square tests or non-parametric equiva-
lents as appropriate, and regression modelling. The pri-
mary outcome analysis will be repeated on all three
outcome collection methods to determine if conclusions
remain the same. We expect little disparity in reporting
of ‘any self-harm episode’ but potentially more in the
time of first episode and number of episodes. If conclu-
sions differ by the collection method used we will inves-
tigate reasons for the discrepancy. From this analysis we
will be more certain of the appropriate collection meth-
ods for self-harm data and be better placed to decide on
the appropriate outcome measure and estimate effective-
ness in a future definitive trial.
Economic evaluation
The economic evaluation will take a broad perspective,
including the cost of all hospital and community health
and social care services and contacts with the criminal
justice system. Resource use information will be col-
lected using a modified version of the Adult Service Use
Schedule (AD-SUS) [23]. These data will also allow us
to record what TAU was actually delivered during the
trial. Resource use data will be combined with appropri-
ate national unit costs to calculate the total cost of the
intervention and control groups. The cost of the JCP
will be directly calculated from salaries using a micro-
costing approach [26]. Differences in mean total costs
between groups will be compared using the standard
t-test with ordinary least squares regression used for
adjusted analyses and the validity of results confirmed
using bootstrapping [27]. The cost-effectiveness of the
intervention will be assessed through the calculation of
incremental cost effectiveness ratios, using the primary
outcome measure and cost-utility will be assessed
through the calculation of QALYs based on the EQ-5D.
Uncertainty around the cost and effectiveness estimates
will be represented using cost-effectiveness acceptability
curves [28].
Process evaluation
A qualitative study will be carried out to explore the
processes through which JCPs work in practice. Nego-
tiating JCP content may clarify treatment issues and
build consensus between service users and staff. How-
ever effects on trust, service user engagement in the
process of care including shared decision making,
changes to service user self esteem and empowerment,
clearer channels of communication between all parties,
changes to staff risk perception and/or changes within
the culture of the mental health service may also be
important. Focus groups will be used to examine peo-
ple’s experience of the JCP and separate service user
and health professional focus groups will be convened.
We anticipate involving approximately 5-10 service
users and 5-10 staff in each of the two groups.
Ethics
The study protocol was approved by South London REC
Office (REC number: 09/H0803/113).
Discussion
Joint Crisis Plans have been shown to to be an effective
way of reducing compulsory treatment in people with
psychosis, but to date, no study has examined their
effectiveness in people with BPD. Despite the fact that
BPD is a prevalent condition associated with increased
mortality and substantial economic costs, treatment
research in this area is still in its infancy. Complex psy-
chological interventions have been shown to be useful
[29], although such treatments are expensive and time-
consuming to deliver and this has limited their availabil-
ity. Less complex interventions are required for the
large proportion of BPD people who are not referred to
specialist services and JCPs may be an effective and
cost-effective intervention [30]. We undertook detailed
developmental work with service users, clinicians and
academics in order to modify JCPs for people with BPD
and to test the feasibility of developing such JCPs in a
busy clinical environment. The plans proved to be both
feasible and potentially useful and we now plan to test
the effectiveness of JCPs in the exploratory trial.
The exploratory trial will gather critical information
about key trial parameters necessary to inform the
design of a definitive trial, including information on can-
didate outcome variables, consent and attrition rates and
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Regarding our choice of primary outcome, currently,
there is no gold standard for reliably measuring episodes
of self-harm [31]. Accordingly, and to enhance the valid-
ity of our data, we will be making use of both contem-
poraneous and retrospective methods to measure
self-harm including self-report, completion of diaries
and electronic patient records. It is equally possible that
whilst the JCP may not influence self-harming behaviour
per se, the production of a JCP might lead to improve-
ments in engagement with services and/or greater satis-
faction in the management of future self-harm events.
For these reasons, we will also be measuring these out-
come domains as secondary outcome variables.
The JOSHUA study has limitations which warrant
mentioning. Firstly, it is not a double-blind study design
and, as such, the participants and certain members of
the research team will be aware of which arm of the
trial each participant has been allocated to. However,
collection and analysis of follow-up data will be blind to
treatment status. In addition there will be specific
instructions to participants and clinical teams not to dis-
close treatment details details at any stage throughout
the study. Every effort will be made to maximise the sin-
gle blindness of research workers, whose ‘best guesses’
of service user status will be assessed after the final
assessment/at the end of the study to test whether their
blindness has been maintained. Secondly, there may be
selective dropout in one arm of the study; as such, we
will examine whether this occurred in the data analysis.
Finally it is not designed as a definitive trial but one
which will give broad indications of effectiveness and
aid the design of a future trial.
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